İlhan Sabancılar | Molecular Oncology | Best Researcher Award

Published on by Global Academic Awards

Assist. Prof. Dr. İlhan Sabancılar | Molecular Oncology | Best Researcher Award

Bitlis Eren University | Turkey

Assist. Prof. Dr. İlhan Sabancılar is a biochemist and medical researcher at Bitlis Eren University, Turkey, whose work bridges biochemistry, molecular medicine, and pharmaceutical sciences. His research primarily focuses on the anticancer, antioxidant, antimicrobial, and anti-inflammatory properties of bioactive compounds, natural extracts, and nanomaterials. Assist. Prof. Dr. İlhan Sabancılar has contributed to the synthesis and biological evaluation of novel heterocyclic and aza-acyclic nucleoside derivatives, investigating their potential as therapeutic agents through molecular docking and cytotoxicity studies. His publications in journals such as Pharmaceuticals, Current Issues in Molecular Biology, and Reviews on Environmental Health reflect his expertise in oxidative stress, trace element biochemistry, and drug development. With 9 publications and 247 citations, he has established a growing scientific presence supported by multiple research projects on oxidative stress, viral inhibition, and cancer therapeutics. A member of the Turkish Biochemical Society and the Molecular Cancer Research Association, Assist. Prof. Dr. İlhan Sabancılar’s multidisciplinary approach and consistent research output position him as a promising scholar contributing significantly to the advancement of biomedical and biochemical sciences.

Profile: Scopus | Orcid | Google Scholar

Featured Publications

1. Unsal, V., Cicek, M., & Sabancilar, İ. (2021). Toxicity of carbon tetrachloride, free radicals and role of antioxidants. Reviews on Environmental Health, 36(2), 279–295.

2. Bilden, A., Sabancılar, İ., Yalçın Azarkan, S., Karadağlı, K., Kaya, S., Kahraman, M., & Çiçek, M. (2025). Investigating the therapeutic potential of crude leech saliva based on its anticancer, antioxidant, and anti-inflammatory effects. Current Issues in Molecular Biology, 47(5), 328.

3. Sabancilar, İ., Unsal, V., Demir, F., Toprak, G., & Pekkolay, Z. (2023). Does oxidative status affect serum sclerostin levels in patients with type 2 diabetes mellitus? Folia Medica, 65(1), 46–52.

4. Alhilal, M., Alhilal, S., Gomha, S. M., Farag, B., Sabancilar, İ., & Ouf, S. A. (2025). Biological evaluation and molecular docking studies of novel aza-acyclic nucleosides as putative antimicrobial, anticancer, and antioxidant agents. BMC Chemistry, 19(1), 255.

5. Muhammed Ayral, H. T., Toprak, S. F., Dedeoğlu, S., & Sabancılar, İ. (2021). Kronik Otitis Media’da Tiyol-Disülfid Homeostazının Değişikliği. Dicle Tıp Dergisi, 48(1), 197–204.

6. Toprak, G., Sabancılar, İ., Özcan, N., & Alkan, H. (2020). Total oxidant status (TOS), total antioxidant status (TAS), ferritin and vitamin D levels in patients with chronic hepatitis C. Microbiology and Infectious Diseases, 4(2), 1–4.

 

Richard Moore | Gynecologic Oncology | Leadership in Research Excellence Award

Published on by Global Academic Awards

Dr. Richard Moore | Gynecologic Oncology | Leadership in Research Excellence Award

University of Rochester | United States

Dr. Richard Moore is a distinguished leader in gynecologic oncology, renowned for his pioneering research, academic excellence, and leadership in translational medicine. He earned degrees in mechanical and industrial engineering before pursuing biology and obtaining his MD from the University of Alberta. His postgraduate training at Eastern Virginia Graduate School of Medicine and fellowship at Brown University established his foundation in women’s oncology. Over his illustrious career, Dr. Richard Moore has held prestigious roles, including Director of the Molecular Therapeutics Laboratory and Center for Biomarkers and Emerging Technology at Brown University, and currently serves as Chief of Gynecologic Oncology and Director of the Targeted Therapeutics Laboratory for Gynecologic Cancers at the University of Rochester Medical Center. A tenured professor, he has contributed significantly to advancing targeted therapeutics, biomarker discovery, and patient-centered oncology care. His work has earned numerous awards, international recognition, and over 8,037 citations from 135 publications and an impressive h-index of 39.

Profile: Scopus

Featured Publications

  • OVARIO Investigators, & Moore, R. G. (2025). A phase 2 trial of niraparib plus bevacizumab maintenance therapy following first-line platinum-based chemotherapy with bevacizumab in advanced ovarian cancer: Final analysis and overall survival results from OVARIO. Gynecologic Oncology.

  • NRG Oncology, & Moore, R. G. (2025). Pembrolizumab plus chemotherapy in advanced or recurrent endometrial cancer: Overall survival and exploratory analyses of the NRG GY018 phase 3 randomized trial. Nature Medicine.

  • Moore, R. G., et al. (2025). First-line lenvatinib plus pembrolizumab versus chemotherapy for advanced endometrial cancer: A randomized, open-label, phase III trial. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology.

  • Moore, R. G., et al. (2025). Endometrioid adenocarcinoma of the colon arising from rare malignant transformation of extra-gonadal endometrioma. Gynecologic Oncology Reports.

  • Moore, R. G., et al. (2025). Estrogen therapy in patients with gynecologic cancer: A survey of gynecologists and oncologists in the United States. Menopause.

Cheng Yi | Oncology | Best Researcher Award

Published on by Global Academic Awards

Mr. Cheng Yi | Oncology | Best Researcher Award

West China Hospital of Sichuan University | China

Mr. Cheng Yi, a distinguished Medical Doctor from Sichuan, currently serves as a professor and doctoral supervisor at the Cancer Center of West China Hospital, Sichuan University, and as an adjunct doctoral supervisor at Chengdu University of Traditional Chinese Medicine. He earned his Bachelor and Master of Medicine from Xi’an Jiaotong University, his Doctor of Medicine from Fudan University, and completed postdoctoral research at the University of Toronto. Since 1996, he has been deeply engaged in oncology clinical practice, scientific research, and teaching, advancing to professor and chief physician in 2006. His academic roles include standing committee and deputy director positions across multiple Chinese medical associations, reflecting his leadership in oncology and integrative medicine. With 138 publications, over 2,422 citations, and an h-index of 26, his research spans nanomedicine, cancer therapeutics, molecular oncology, immunotherapy, and systematic reviews, with impactful studies published in Journal of Materials Chemistry B, Nano Research, Frontiers in Oncology, PLoS One, and Journal of Cancer Research and Clinical Oncology. His international experience and consistent contributions to cancer treatment innovation highlight his strong candidacy for the Best Researcher Award, showcasing excellence in scientific impact, academic mentorship, and translational oncology research.

Profile: Scopus | Orcid

Featured Publications

Zhang, L.-N., Wei, Y.-F., Ran, X.-Y., Shi, L., Wang, Z.-Y., Chen, S.-Y., Yi, C., Yu, X.-Q., & Li, K. (2025). Liberating exciton transfer as a pioneering strategy to construct type I photosensitizers for hypoxia deep-seated metastases suppression. JACS Au. Advance online publication.

Tan, S., Feng, M., Zhou, N., Zhang, S., Yi, C., & Gou, H. (2025). DNA damage response and repair gene mutations predict clinical outcomes in biliary tract cancer. Cancer. Advance online publication.

Chen, P., Hou, W., Li, C., Liang, Q., Ma, L., Zhao, X., & Yi, C. (2025). Lived experiences of patients with advanced pancreatic cancer on patient-reported outcomes (PROs) management: A qualitative phenomenological study in Southwest China. BMJ Open, 15(1), e084259.

Ran, X.-Y., Xia, W.-L., Zhang, L.-N., Yu, X.-Q., Chen, P., Xie, K.-P., Zhao, Y., Yi, C., & Li, K. (2024). De novo design of type-I photosensitizer agents based on structure-inherent low triplet energy for hypoxia photodynamic therapy. Materials Horizons. Advance online publication.

Tan, S., Zhang, S., Zhou, N., Cai, X., Yi, C., & Gou, H. (2023). Efficacy and safety of fruquintinib dose-escalation strategy for elderly patients with refractory metastatic colorectal cancer: A single-arm, multicenter, phase II study. Cancer Medicine, 13(1), e6786.

Wei, Y., Zheng, L., Yang, X., Luo, Y., Yi, C., & Gou, H. (2023). Identification of immune subtypes and candidate mRNA vaccine antigens in small cell lung cancer. The Oncologist, 28(11), oyad193.

Portia Nkhumbuleni Ramashia | Radiation Oncology | Best Researcher Award

Published on by Global Academic Awards

Ms. Portia Nkhumbuleni Ramashia | Radiation Oncology | Best Researcher Award

Ms. Portia Nkhumbuleni Ramashia, University of Johannesburg, South Africa

Ms. Portia Nkhumbuleni Ramashia is an experienced Radiation Therapist and academic, currently serving as a Radiotherapy Lecturer at the University of Johannesburg (UJ). With extensive experience in both public and private healthcare sectors, she is known for her leadership, analytical thinking, and ability to mentor colleagues in delivering high-quality oncology care. As a Research Ethics Committee Member and Departmental Research Committee Chairperson, she plays a key role in ensuring research integrity and policy adherence. Passionate about healthcare innovation and education, she supervises master’s students and actively contributes to global oncology research. 🌍📚

Publication Profile

Orcid

🎓 Education

Ms. Ramashia holds a Master of Technology in Radiography (2017), B-Tech in Radiation Therapy (2009), and a National Diploma in Radiation Therapy (2006) from the University of Johannesburg. She is currently pursuing a PhD in Public Health at UJ, focusing on healthcare access, quality, and cancer treatment advancements. Her academic journey reflects a strong commitment to radiotherapy excellence and public health research. 🎓🔬

💼 Experience

With over a decade of experience, Ms. Ramashia has excelled as a Radiation Therapy Lecturer at UJ since 2018, developing innovative teaching methodologies and supervising master’s students. She chairs research committees, ensuring compliance with faculty policies, and engages in multidisciplinary collaborations. As a Radiation Therapist, she has worked in both public and private healthcare, pioneering strategies to enhance radiotherapy access and quality. She frequently presents her research at global conferences, influencing radiotherapy practices worldwide. 🏥📖

🏆 Awards & Honors

Ms. Ramashia has been recognized for her academic and research contributions, securing the NRF Black Academic Advancement Program (BAAP) Grant (2024) and being invited to the 2024 NRF Next Generation and Emerging Researchers Symposium. She has also been selected to attend the prestigious 16th HOPE Meeting with Nobel Laureates (2025). Her achievements highlight her impact on oncology research and academic excellence. 🏅🔬

🔬 Research Focus

Her research interests span cancer treatment effectiveness, healthcare disparities, health economics, global health, and quality improvement in radiotherapy. She explores barriers to radiotherapy access in Sub-Saharan Africa, evaluates novel radiotherapy planning tools, and investigates strategies for enhancing survivorship care. Her work contributes to policy development and innovative solutions in oncology. 🌍🩺

Publication Top Notes

📌 Improving Access to Radiotherapy Services in Gauteng: Quantitative Analysis of Key Time Intervals from Diagnosis to Treatment (2025) – International Journal of Environmental Research and Public Health 🔬📊 | DOI: 10.3390/ijerph22040544

📌 Barriers to Radiotherapy Access in Sub-Saharan Africa for Patients with Cancer: A Systematic Review (2024) – International Journal of Environmental Research and Public Health 🌍🏥 | DOI: 10.3390/ijerph21121597

📌 Radiography Managers’ Perceptions on Skills Required in Public Health Institutes in Gauteng (2024) – Health SA Gesondheid 🏥📑 | DOI: 10.4102/hsag.v29i0.2654

📌 Radiotherapy Plan Evaluation Tool in a Resource-Limited Setting: Comparison of VERT and Treatment Planning Software (2023) – Journal of Medical Imaging and Radiation Sciences ⚡📊 | DOI: 10.1016/j.jmir.2023.07.014

📌 The Experiences of Mine Workers with Cancer (2018) – Health SA Gesondheid ⛏️🎗️ | DOI: 10.4102/hsag.v23i0.1176

Conclusion

Ms. Portia Nkhumbuleni Ramashia’s contributions to radiotherapy research, cancer care disparities, and healthcare quality improvement position her as a strong candidate for the Research for Best Researcher Award. Her extensive publication record, academic leadership, research ethics involvement, and international recognition affirm her commitment to impactful and transformative research.

Tianzhu Qiu | Oncology | Women Researcher Award

Published on by Global Academic Awards

Prof. Dr. Tianzhu Qiu | Oncology | Women Researcher Award

Prof. Dr. Tianzhu Qiu, the First Affiliated Hospital with Nanjing Medical University, China

Prof. Dr. Tianzhu Qiu is an esteemed oncology expert with a Ph.D. in Medicine from Nanjing Medical University. She serves as an Associate Chief Physician at Jiangsu Provincial People’s Hospital, specializing in colorectal cancer and immunotherapy. With a strong background in tumor microenvironment studies, mitochondrial autophagy, and immune mechanisms, she has led multiple clinical and translational research projects. She is actively involved in academic leadership, holding key positions in the Chinese Medical Doctor Association and the Chinese Anti-Cancer Association. As a prolific researcher, she has published over 10 SCI-indexed papers, contributed to national guidelines, and received numerous accolades, including the Jiangsu Medical Science and Technology Awards. Dr. Qiu is also a patent holder and a Deputy Editor of medical guidelines, showcasing her contributions to oncology research and healthcare innovation.

Publication Profile

Scopus

Education 🎓

Prof. Dr. Tianzhu Qiu earned her Ph.D. in Medicine from Nanjing Medical University, a leading institution known for its advanced medical research and education. Her academic journey was focused on oncology, particularly exploring colorectal cancer, immunotherapy, and tumor microenvironment mechanisms. During her doctoral studies, she gained expertise in single-cell transcriptomics, proteomics analysis, and high-dimensional immunofluorescence techniques, which have significantly contributed to her research. She further specialized in mitochondrial autophagy and immune response mechanisms, refining her technical skills in bioinformatics and molecular biology. Her Ph.D. research laid the foundation for her later work in translational oncology, where she has made significant breakthroughs in understanding cancer progression and treatment. Through continuous learning and collaboration with global experts, she has positioned herself as a leading figure in oncology research, contributing to both academic and clinical advancements in cancer treatment.

Experience 🏥

Dr. Tianzhu Qiu has extensive experience in oncology, serving as an Associate Chief Physician at Jiangsu Provincial People’s Hospital. She has led clinical and translational research, focusing on colorectal cancer, immunotherapy, and tumor microenvironment studies. Her work involves conducting advanced studies on mitochondrial autophagy and immune mechanisms, aiming to enhance treatment effectiveness and patient outcomes. She has played a key role in multiple national and provincial research projects, acting as Principal Investigator and Co-Investigator. Additionally, she has actively contributed to medical academia, serving as Secretary & Member of the Immunotherapy Committee of Colorectal Cancer and holding leadership positions in oncology-related committees. Her research has been instrumental in developing innovative cancer treatment strategies, and she has contributed to national medical guidelines. Through her experience, Dr. Qiu continues to bridge the gap between fundamental cancer research and clinical application, improving therapies and patient care.

Awards & Honors 🏆

Dr. Tianzhu Qiu has been recognized for her outstanding contributions to oncology with prestigious awards. She has received the First Prize and Second Prize in the Jiangsu Medical Science and Technology Awards for her innovative research in colorectal cancer and immunotherapy. These honors highlight her pioneering work in tumor microenvironment studies, mitochondrial autophagy, and immune response mechanisms. Her groundbreaking research has also earned her multiple research grants and leadership positions in oncology-related committees. As an esteemed researcher, she has been invited to present her work at top conferences, including ASCO-GI and ICIMH. Additionally, she has been granted eight patents for her innovative cancer treatment methodologies. Her contributions to oncology are further acknowledged through her role as Deputy Editor of the CACA Exercise Rehabilitation Guidelines. These accolades solidify her reputation as a leading oncology researcher, continuously advancing cancer treatment strategies.

Research Focus 🔬

Dr. Tianzhu Qiu’s research is centered on colorectal cancer, immunotherapy, and tumor microenvironment dynamics. She has made significant contributions to understanding mitochondrial autophagy and its role in cancer progression. Her work also involves single-cell transcriptomics and proteomics analysis, helping to uncover novel biomarkers and therapeutic targets. Utilizing advanced techniques such as multiplex immunofluorescence and high-dimensional bioinformatics, she has developed new approaches for cancer diagnosis and treatment. Her research extends into humanized mouse models to study tumor behavior and immune response in real-time. As Principal Investigator and Co-Investigator in multiple national and provincial projects, she has contributed to major advancements in cancer therapy. Her work has been widely published, with over 400 citations in SCI-indexed journals. By bridging molecular research with clinical applications, she continues to drive innovations in precision oncology and immunotherapy, improving outcomes for cancer patients worldwide.

 

Publication Top Notes

1️⃣ Evaluating AI in medicine: a comparative analysis of expert and ChatGPT responses to colorectal cancer questions – Scientific Reports, 2024 📆 | Cited by: 10 📑

2️⃣ Neoadjuvant sintilimab and chemotherapy in patients with potentially resectable esophageal squamous cell carcinoma (KEEP-G 03): An open-label, single-arm, phase 2 trial – Journal for ImmunoTherapy of Cancer, 2023 📆 | Cited by: 42 📑

Conclusion

Prof. Dr. Tianzhu Qiu is a highly accomplished researcher in oncology, with significant contributions to colorectal cancer treatment, immunotherapy, and tumor microenvironment studies. Her leadership roles, strong publication record, research innovations, and national recognition make her an outstanding candidate for the Research for Women Researcher Award.

Maryam Azizi | food packaging | Best Researcher Award

Published on by Global Academic Awards

Assoc Prof Dr. Maryam Azizi | food packaging | Best Researcher Award

Assoc Prof Dr. Maryam Azizi, Iran

Dr. Maryam Azizi is an Associate Professor in Iran, specializing in [insert specific field, e.g., molecular biology, nanotechnology, etc.]. With a distinguished academic career, she has significantly contributed to [insert specific area of research or notable contributions]. Dr. Azizi holds a Ph.D. from [insert university name], and her research interests include [list key research interests]. She has published numerous papers in esteemed scientific journals and has been a pivotal figure in various research projects and conferences. Dr. Azizi is also dedicated to mentoring the next generation of scientists and researchers, making substantial impacts in both academia and the broader scientific community.

Publication profile

🎓 Education :

Tabriz University of Medical Sciences, Faculty of Health and Nutrition,Ph.D. in Food Science and Technology,2017-2021
Supervisors: Dr. Ali Ehsani and Dr. Babak Ghanbarzadeh
Thesis: Design of nanobiocomposite of polyvinyl alcohol-gelatin-zeolite 4A containing metal nanoparticles (titanium dioxide and zinc oxide) and its application to increase the shelf life of shrimp,Master’s in Food Science and Technology
2011-2014,Supervisor: Dr. Mohammad Alizadeh
Thesis: The effect of replacement of stevia and dates with sugar on physicochemical, sensory, rheological and glycemic index of ice cream,Shahid Beheshti University of Medical Sciences, Faculty of Nutrition and Food,Bachelor’s in Nutrition and Food Science,2007-2011

 Experience:

Tabriz University of Medical Sciences, Faculty of Nutrition and Food Science,Research Director
2020-2021
Managed and directed research activities within the faculty.,Director of Student Research Committee
2020-2021
Led the student research initiatives, fostering an environment for academic growth and innovation.,Director of the Virtual Examinations Committee
2020-2021,Oversaw the implementation and management of virtual examinations within the faculty.,Member of the Cultural Council
2021,Contributed to the cultural and academic development of the faculty.

Key Areas of Research Expertise:

  • Food packaging (antimicrobial, smart, biodegradable, and nanocomposite packaging)
  • Investigation of food pollution and toxins with an emphasis on seafood

Awards:

Best Researcher Award,Awarded by Tabriz University of Medical Sciences for outstanding research contributions in 2021.,Top Graduate Student,Recognized as the top graduate student in the Faculty of Health and Nutrition in 2014.,Best Thesis Award,Received for the thesis titled “Design of nanobiocomposite of polyvinyl alcohol-gelatin-zeolite 4A containing metal nanoparticles (titanium dioxide and zinc oxide) and its application to increase the shelf life of shrimp” in 2021.

Publication Top Notes

State-of-the-art nanosensors and kits for the detection of antibiotic residues in milk and dairy products Abedi-Firoozjah, R., Alizadeh-Sani, M., Zare, L., … Lin, X., Jafari, S.M.

Enhanced carbohydrate-based plastic performance by incorporating cerium-based metal-organic framework for food packaging application Jafarzadeh, S., Golgoli, M., Azizi-Lalabadi, M., … Rabiee, N., Zargar, M.
Nanomaterial-based sensors for the detection of pathogens and microbial toxins in the food industry; a review on recent progress Abedi-Firoozjah, R., Ebdali, H., Soltani, M., … Zhang, F., Jafari, S.M
Starch-gelatin blend films: A promising approach for high-performance degradable food packaging Zhang, W., Azizi-Lalabadi, M., Jafarzadeh, S., Jafari, S.M.
Maillard-reaction (glycation) of biopolymeric packaging films; principles, mechanisms, food applications Zhang, W., Azizi-Lalabadi, M., Roy, S., … Castro-Muñoz, R., Jafari, S.M.

Fatemeh Moradian | Cancer Award | Best Researcher Award

Published on by Global Academic Awards

Assoc Prof Dr. Fatemeh Moradian | Cancer Award | Best Researcher Award

Assoc Prof Dr. Fatemeh Moradian,Sari Agricultural Sciences and Natural Resources University, Iran

Dr. Fatemeh Moradian is an Associate Professor with a PhD in Biochemistry, specializing in enzymes and cancer mechanisms. She taught at Sari Agricultural Sciences and Natural Resources University for 13 years. Her research spans diverse conferences globally, focusing on biochemistry, microbiology, and biotechnology. Dr. Moradian’s extensive publications include studies on proteases, enzymes, and their applications in health and agriculture. She has conducted sabbatical research at the University of Alberta, Canada. Her work on lactoferrin and its antimicrobial and anticancer effects highlights her contributions to biomedical sciences. 🧬🔬

 

Publication profile

🎓 Education and Academic Background

Fatemeh (Elham) Moradian holds a PhD in Biochemistry and is an Associate Professor, having earned her Bachelor’s degree in Biology from the University of Shiraz in 1996, followed by a Master’s and PhD in Biochemistry from the University of Tarbiat Modares in 2000 and 2006, respectively.

📚 Teaching Experience

She has enriched the academic community through her expertise in Biochemistry, Enzymology, Biochemical Mechanisms of Cancer, Animal Cell Culture, and Bioinformatics. Her teaching tenure spans from 2006 to 2019 at Sari Agricultural Sciences and Natural Resources University.

Research Focus

Based on the cited research publications, F. Moradian’s research focus primarily revolves around enzymology, biotechnology, and environmental applications. Moradian has contributed significantly to the isolation, purification, and characterization of enzymes such as α-amylase and protease from Bacillus species, highlighting their stability and applications in various industrial sectors. Additionally, their work extends to environmental sciences, particularly in the treatment of landfill leachate using advanced oxidation processes. Moradian has also explored the biomedical aspects of proteins like lactoferrin, emphasizing its antimicrobial and anticancer properties. Overall, Moradian’s research spans enzyme technology, bioprocessing, environmental remediation, and bioactive molecule applications. 🧪🌱

 

Publication Top Notes

Ken Kato | Oncology Award | Excellence in Research

Published on by Global Academic Awards

Dr. Ken Kato | Oncology Award | Excellence in Research

Dr. Ken Kato, National Cancer Center Hospital, Japan

Dr. Ken Kato is a distinguished Japanese oncologist specializing in gastrointestinal and esophageal cancers. With a robust career at the National Cancer Center Hospital in Tokyo, he leads divisions in translational research and medical oncology 🏥. Holding both an M.D. and a Ph.D. from prestigious institutions 🎓, Dr. Kato has a notable presence in clinical and research domains, with expertise in molecular targets and immunotherapy for cancer 🧬. His extensive publications in top medical journals highlight his dedication to advancing cancer treatment 📚. Dr. Kato is also an active member of several professional societies worldwide 🌏.

Publication profile

Scopus

Education

Dr. Kato earned his Ph.D. from Kyushu University in 2001 and his M.D. in 1995. He graduated from the University of Occupational and Environmental Health in 1989 🎓.

Research Focus

Dr. Ken Kato is a leading researcher in gastrointestinal and esophageal cancers, focusing primarily on early detection, treatment, and the molecular mechanisms of these malignancies 🧬. His work includes innovative studies on serum microRNAs for early gastric cancer detection, biomarkers for chemotherapy response, and the genetic underpinnings of cancer resistance 📊. He has explored the efficacy of various chemotherapeutic combinations, such as S-1 plus cisplatin for HER2-positive gastric cancer, and has investigated the impact of gene mutations in treatment outcomes 🚑. Dr. Kato’s research aims to advance precision medicine in oncology, improving patient survival and treatment efficacy 🌟.

Publication Top Notes

  • A novel combination of serum microRNAs for the detection of early gastric cancer – Abe, S., Matsuzaki, J., Sudo, K., … Saito, Y., Ochiya, T. Gastroenterological Endoscopy, 2021, 63(6), pp. 1310 📅, Cited by: 0 🔍
  • ZNF695 methylation predicts a response of esophageal squamous cell carcinoma to definitive chemoradiotherapy – Takahashi, T., Yamahsita, S., Matsuda, Y., … Nagino, M., Ushijima, T. Journal of Cancer Research and Clinical Oncology, 2015, 141(3), pp. 453–463 📅, Cited by: 21 📊
  • Efficacy of S-1 plus cisplatin combination chemotherapy in patients with HER2-positive advanced gastric cancer – Honma, Y., Shimada, Y., Takashima, A., … Sekine, S., Kushima, R. International Journal of Clinical Oncology, 2014, 19(5), pp. 863–870 📅, Cited by: 3 📈
  • Clinicopathological features and prognostic roles of KRAS, BRAF, PIK3CA and NRAS mutations in advanced gastric cancer – Takahashi, N., Yamada, Y., Taniguchi, H., … Hamaguchi, T., Shimada, Y. BMC Research Notes, 2014, 7(1), 271 📅, Cited by: 41 🔬
  • Clinical impact of c-MET expression and genetic mutational status in colorectal cancer patients after liver resection – Shoji, H., Yamada, Y., Taniguchi, H., … Hamaguchi, T., Shimada, Y. Cancer Science, 2014, 105(8), pp. 1002–1007 📅, Cited by: 24 🧬
  • Combined Assessment of Endothelial Growth Factor Receptor Dual Color In Situ Hybridization and Immunohistochemistry with Downstream Gene Mutations in Prediction of Response to the Anti-EGFR Therapy for Patients with Metastatic Colorectal Cancer – Takahashi, N., Yamada, Y., Taniguchi, H., … Hamaguchi, T., Shimada, Y. Archives of Medical Research, 2014, 45(5), pp. 366–374 📅, Cited by: 7 🔍
  • A phase II study of nedaplatin and 5-fluorouracil in metastatic squamous cell carcinoma of the esophagus: The Japan Clinical Oncology Group (JCOG) Trial (JCOG 9905-DI) – Kato, K., Muro, K., Ando, N., … Nagai, K., Kato, H. Esophagus, 2014, 11(3), pp. 183–188 📅, Cited by: 30 🩺
  • Survival prolongation after treatment failure of first-line chemotherapy in patients with advanced gastric cancer: Combined analysis of the Japan Clinical Oncology Group Trials JCOG9205 and JCOG9912 – Takashima, A., Boku, N., Kato, K., … Shimada, Y., Ohtsu, A. Gastric Cancer, 2014, 17(3), pp. 522–528 📅, Cited by: 26 📊
  • Biomarkers of reactive resistance and early disease progression during chemotherapy plus bevacizumab treatment for colorectal carcinoma – Hayashi, H., Arao, T., Matsumoto, K., … Nishio, K., Yamada, Y. Oncotarget, 2014, 5(9), pp. 2588–2595 📅, Cited by: 33 🧪
  • Feasibility of endoscopic mucosal resection as salvage treatment for patients with local failure after definitive chemoradiotherapy for stage IB, II, and III esophageal squamous cell cancer – Makazu, M., Kato, K., Takisawa, H., … Yamada, Y., Shimada, Y. Diseases of the Esophagus, 2014, 27(1), pp. 42–49 📅, Cited by: 31 🩹